Invitrogen™ Inotuzumab Humanized Recombinant Human Monoclonal Antibody

Human Recombinant Monoclonal Antibody

Supplier:  Invitrogen™ MA541854

Catalog No. PIMA541854

Description

Endotoxin level < 0.01EU/μg by LAL method Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8 °C for one week. Store at -20 to -80 °C for twelve months from the date of receipt.

Inotuzumab ozogamicin is an antibody-pharmaceutical conjugate using linker and cytotoxic pharmaceutical technology similar to that developed for the ground-breaking treatment Mylotarg (Gemtuzumab ozogamicin), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukemia. Inotuzumab ozogamicin consists of a recombinant humanized IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent 4. Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with high mortality rates and low therapeutic response from standard chemotherapies in relapsing conditions. In a randomized trial, inotuzumab ozogamicin displayed higher percentages of patients undergoing longer periods of complete remission with no evidence of disease in comparison to patients receiving alternative chemotherapy 5.

Specifications

• Antigen: Inotuzumab Humanized
• Classification: Recombinant Monoclonal
• Conjugate: Unconjugated
• Gene Alias: CMC-544
• Immunogen: Human CD22.
• Quantity: 100 μg
• Primary or Secondary: Primary
• Content And Storage: -20°C, Avoid Freeze/Thaw Cycles
• Form: Liquid
• Target Molecule: Chemical

• Applications: ELISA, SDS-Page
• Concentration: 2.7 mg/mL
• Formulation: PBS with no preservative; pH 7.4
• Host Species: Human
• Purification Method: Protein A
• Regulatory Status: RUO
• Target Species: Human
• Product Type: Antibody
• Isotype: IgG4 κ

Safety and Handling

WARNING: Cancer - www.P65Warnings.ca.gov